Cover Image
市場調查報告書

C型肝炎:KOL (關鍵意見領袖) 分析

Hepatitis C: KOL Insight

出版商 FirstWord 商品編碼 344321
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
C型肝炎:KOL (關鍵意見領袖) 分析 Hepatitis C: KOL Insight
出版日期: 2016年09月01日 內容資訊: 英文
簡介

本報告以C型肝炎的7種已上市藥物及開發階段的6種藥物為研究主題,提供北美及歐洲的12名關鍵意見領袖(KOL) 的各種見解彙整。

調查對象藥物範例

  • Harvoni (sofosbuvir/ledipasvir; Gilead)
  • Sovaldi (sofosbuvir; Gilead)
  • Viekira Pak/Viekirax+Exviera (paritaprevir/ ombitasvir/ dasabuvir; AbbVie/Enanta)
  • Zepatier (elbasvir/grazoprevir; Merck & Co.)等

主要的論點

  • 了解KOLHCV治療途徑的合理化有改善空間
    • KOL有考慮除了Ribavirin以外的未來具潛力候補嗎
  • FDC:懷疑單劑治療的有益性
    • 專家對單劑療法 (Sovaldi、Olysio、Daklinza等)的未來性的想法
  • 政府提高HCV篩檢率的措施,同意是有限的成功
    • KOL認為在哪裡有未滿足需求
  • 專家認為現有的藥物能有效治療一般的遺傳基因型大部分的患者
  • 全部的遺傳基因型的療法:HCV治療範例朝向簡便化
  • 決定HCV藥的市場上的利用可能性的主要原因,許多國家是成本
    • 關於這個KOL的看法
  • 專家對新途徑作為標的的開發平台藥物引起興趣嗎
    • Regulus Therapeutics的RG-101,Biotron的BIT225等
    • 安全性簡介,市場潛在性相關的KOL的意見為何?等

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 596200594

As hepatitis C cures multiply, how do experts evaluate the options?

Since the launch of Sovaldi (sofosbuvir; Gilead) in 2013, the hepatitis C (HCV) landscape has developed at a rapid pace. The focus has shifted to cure, and physicians now have more treatment options than ever. But which ones should they use? Key opinion leaders provide their views, as well as give their candid insights on which regimens of the future could change treatment the HCV treatment paradigm again.

Covering 7 currently marketed drugs and 6 pipeline therapies, this report reveals candid insights about the HCV landscape from 12 KOLs in North America and Europe. You'll learn which treatments KOLs have confidence in, which ones they question - and which ones they think can challenge the standard of care in the future.

"Even with the new drugs coming into the market, Harvoni's eight-week treatment regimen is a strong argument for Gilead to keep it on the market ... I do not see Epclusa or Zepatier getting into that segment. The only other drug that can be a challenge to Harvoni is [ABT- 493/ABT-530], because they have eight-week results for every population so far." US KOL

Sample of brands covered:

  • Harvoni (sofosbuvir/ledipasvir; Gilead)
  • Sovaldi (sofosbuvir; Gilead)
  • Viekira Pak/Viekirax+Exviera (paritaprevir/ ombitasvir/ dasabuvir; AbbVie/Enanta)
  • Zepatier (elbasvir/grazoprevir; Merck & Co.)
  • Plus 9 more

Sample of KOLs interviewed

  • Adrian M. Di Bisceglie. Chief of Hepatology, Division of Gastroenterology and Hepatology, St. Louis University Liver Center, St. Louis, MO.
  • Eric Lawitz. Medical Director, Texas Liver Institute and Clinical Professor of Medicine, University of Texas Health Science Center, San Antonio, TX.
  • Geoffrey Dusheiko. Emeritus Professor of Medicine, Royal Free Hospital and University College School of Medicine, London, UK.
  • Peter Ferenci. Professor of Medicine, Medical University of Vienna, Vienna, Austria.
  • Plus 8 more - download the full list now

Top Takeaways

  • KOLs see room for improvement in streamlining the route to HCV cure. Do KOLs believe there is a future without ribavirin? What else is on their wish lists?
  • FDCs have challenged the utility of single-agent therapies. Do experts believe that monotherapies, including Sovaldi, Olysio and Daklinza, have a future role in treatment?
  • KOLs agree that governments' good intentions to increase rates of HCV screening have had limited success. Beyond identifying more patients, where do KOLs see unmet needs in HCV?
  • Experts concur that existing drugs can successfully treat most patients with the common HCV genotypes. With little room for improving SVR rates, where do KOLs see the biggest opportunities for new entrants addressing these genotypes?
  • Pan-genotypic regimens stand to simplify the HCV treatment paradigm. Other than simplicity, what do KOLs expect from other pan-genotypic therapies in development?
  • Cost is the main factor determining the market availability of HCV drugs in many countries. How do KOLs feel about this?
  • Experts are intrigued by pipeline drugs targeting new pathways. Regulus Therapeutics' RG-101 and Biotron's BIT225 look interesting, but how do KOLs view their safety profile and market potential?

Ongoing Benefits

The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date.
  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date.
Back to Top